Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Tech Xplore on MSN
Interlaced origami structure enables compact storage and high-strength robotic deployment
Researchers at the Department of Mechanical Engineering, Seoul National University, have applied the principle of interlacing ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback